In this article
Eli Lilly
opposes the White House’s push to codify “most favored nation” drug pricing into law, CEO Dave Ricks said in an interview with CNBC.
Lilly is one of more than a dozen drugmakers that signed deals with the Trump administration last year agreeing to charge similar prices for prescription drugs in the U.S. as in other wealthy nations. President Donald Trump has long complained that Americans pay high prices to subsidize low prices for medicine in the rest of the world.
The pharmaceutical industry thought the agreements would pacify those concerns and thwart attempts to make “most favored nation” pricing the law. But the White House in recent months has pushed Congress to codify elements of the deals. The draft text hasn’t been shared publicly, though the administration has said it’s trying to get pharmaceutical companies to back the effort.
